Induction And Analgesia During Labor Flashcards
Pharmacology of Parturition (Labor) - 4
- Pharmacologically relevant targets in parturition regulate smooth muscle contraction
- Tocolytics PREVENT/DELAY labor onset by REDUCING smooth muscle contraction
- Oxytocics (a.k.a. uterotonics) INDUCE labor by PROMOTING smooth muscle contraction
- Pathways converge on myosin light-chain kinase (MLCK)
Myosin light-chain kinase (MLCK) and Uterine Muscle (3)
- ACTIVE MLCK is essential in smooth muscle CONTRACTION
- MLCK is ACTIVATED by Ca2+/calmodulin complex
- Myometrial cell CONTRACTION is mediated by increased Ca2+ levels - MLCK is DEACTIVATED by phosphorylation
- Myometrial cell RELAXATION is promoted by phosphorylation of MLCK
Pharmacological targets of MLCK activity (2)
- Agonism of CRH, PGE2, and ß2-adrenergic receptors promotes RELAXATION
- Agonism of Gs coupled-receptors INCREASES cAMP-mediated PHOSPHORYLATION - Agonism of thrombin, oxytocin, and prostaglandin F receptors promotes CONTRACTION
- Agonism of Gq coupled-receptors INCREASES intracellular Ca2+ levels
General Principles of Tocolytic Pharmacology (3)
- Preterm delivery = delivery occurring before 37 weeks of gestation
- > 10% of pregnancies in the U.S. are preterm
- Associated with neonatal respiratory distress syndrome, pulmonary hypertension, and intracranial hemorrhage - Tocolytic agents are effective in delaying preterm delivery in ~80% of women
- Indicated when delaying delivery up to 48 hours is beneficial to fetus and cervical dilation is not advanced
- Generally not used past 34 weeks gestation - These agents do not decrease overall occurrence of preterm labor or alleviate complications!
Tocolytics postpone delivery long enough to: (3)
- Administration of corticosteroids to the fetus to promote fetal lung development
- Transportation to a facility equipped to deal with high-risk deliveries
- Prolongation of pregnancy in the presence of underlying, self-limited conditions that can cause labor
- E.g., pyelonephritis, abdominal surgery, or other conditions unlikely to cause recurrent preterm labor
Pregnancy can be prolonged by 48 hours to 1 week
Contraindications of tocolytic therapy (8)
- Previability
- Intrauterine fetal demise
- Lethal fetal anomaly
- Intrauterine infection
- Fetal distress
- Severe preeclampsia
- Vaginal bleeding
- Maternal hemodynamic instability
General MOA of Tocolytic Agents and their Classes (2 MOA, 6 Classes)
- Decreased Ca2+/calmodulin availability (decreases uterine contractility)
- Increased phosphorylation (increases uterine relaxation)
Most effective classes:
- COX inhibitors
- Ca2+ channel blockers
- B2-adrenergic receptor agonists
Less effective classes:
- Oxytocin receptor antagonists
- MgSO4 (magnesium sulfate)
- Nitric oxide (NO) donors
COX inhibitors: indomethacin (General, MOA, PK, ADRs, contraindications)
General: First-line agent for tocolysis between 24-32 weeks of gestation
MOA: Non-specific COX inhibitor (reduced PGF synthesis). Reduce stimulation of uterine contractions by decreasing available intracellular Ca2+.
PK: Administered orally or rectally
Maternal ADRs:
- COX-2 inhibitors carry BLACK BOX WARNING: CV toxicity (myocardial infarction, stroke)
- Risk of inhibited platelet function
- N/V, GERD, gastritis, and emesis
Fetal ADRs:
- May induce closure in utero of ductus arteriosus causing impaired circulation
- May reduce amniotic fluid and cause oligohydramnios
Contraindicated beyond 32 weeks of gestation
Ca2+ channel blockers: Nifedipine (General, MOA, PK, ADRs)
General: First-line agent for tocolysis between 32-34 weeks of gestation or for contraindication to indomethacin (24-32 weeks)
MOA: Blocks voltage-gated Ca2+ channels. Reduces stimulation of uterine contractions.
PK: Administered parenterally or orally
Maternal ADRs:
- Peripheral vasodilator: headache, flushing, and dizziness, palpitations, severe hypotension possible
- No direct effect on pacemaking or AV node conduction
- Safer than ß2-adrenergic agonists
No discernible impact on fetus.
Selective B2-adrenergic receptor agonists: terbutaline and ritodrine (General, MOA, PK, ADRs)
General: Terbutaline is FDA-approved for asthma with off-label tocolytic use. Used as second-line agents for 32-34 weeks of gestation.
MOA: B2-adrenergic receptor agonists RELAX myometrium by stimulating cAMP and MLCK phosphorylation.
PK: Administered PO, IV, or subcutaneously
Maternal ADRs:
- Tachycardia, hypotension, pulmonary edema, metabolic effects
- BLACK BOX WARNING: maternal cardiotoxicity and death with prolonged use
Fetal ADRs:
- Drug crosses the placenta
- Similar ADR profile as maternal side
*Ritodrine was FDA-approved for tocolysis, but has been withdrawn from market due to unfavorable ADRs
Oxytocin receptor antagonists: Atosiban (MOA, PK, ADRs)
MOA: Decreases intracellular Ca2+ concentration and decreases uterine contractions. Mimics effectiveness of B2-adrenergic receptor agonists.
PK: Administered IV for 2-48 hours
ADRs:
- Hypersensitivity
*Not FDA approved
MgSO4 and NO (MOA, PK, ADRs, and Contraindications)
MgSO4
MOA: Competes with Ca2+ at voltage-gated and ligand-gated Ca2+ channels. Decreases intracellular Ca2+ and decreases uterine contractions. Also used to treat preeclampsia.
PK: Administered parenterally. Renally excreted.
Maternal ADRs:
- Diaphoresis, flushing, Mg2+ toxicity
Fetal ADRs:
- Bone abnormalities with long-term exposure
Contraindicated in myasthenia gravis, cardiac compromise.
NO
MOA: Activates phosphokinase G via cGMP signaling to phosphorylate MLCK and promote uterine relaxation.
Contraindicated in hypotensive patients.
Indications for Agents Used to Induce Labor - Oxytocics (Uterotonics) - Maternal Factors (9) and Fetal Factors (9)
Maternal factors:
- Preeclampsia
- Eclampsia
- HELLP (hemolysis, elevated liver enzymes, low platelet count)
- Diabetes (pregestational or gestational)
- Chronic hypertension
- Heart disease
- Intrauterine infection
- Augmentation of protracted labor
- Postpartum hemorrhage (uterine atony)
Fetal factors:
- Late-term or postterm pregnancy
- Fetal abnormality
- Chorioamnionitis
- Premature rupture of membranes
- Placental insufficiency
- Oligohydramnios
- Suspected intrauterine growth restriction
- Fetal demise
- Multiple gestation
Prostaglandins, Oxytocin, and Parturition (4)
- PGE2 and oxytocin are required for the onset of parturition
- PGE2 or PGF2a produces DOSE-DEPENDENT increases in:
- Uterine tone
- Frequency of contractions
- Intensity of contractions - Effects of prostaglandins increase as pregnancy progresses
- Prostaglandins and oxytocin used in sequence to promote cervical ripening and induction, respectively
Prostaglandin Agents (Dinoprostone and Misoprostol) MOA and PK
Indications: Cervical ripening prior to labor induction
- Dinoprostone (PGE2) (FDA-approved)
- Available as a gel
- Administered intracervically or as a vaginal insert (next to cervix) - 12 hours for cervical ripening, remove 30 minutes prior to induction, induce with oxytocin - Misoprostol (PGE1) (off-label use)
- Available in tablets that can be administered orally, vaginally, or rectally
- Allow at least 4 hours before induction with oxytocin